However, in the recently updated 2022 ELN recommendations, the FLT3-ITD allelic ratio was no longer considered in risk stratification, with AML with FLT3-ITD mutation included in the intermediate risk group, irrespective of the presence of NPM1 mutation [4]. The gene discussed is NPM1; the disease is acute myeloid leukemia.